| 1 |
Kröger N,Achterrath W, Hegewisch-Becker S, et al. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev,1999,25(5):279-291.
|
| 2 |
Schwartz GF,Meltzer AJ,Lucarelli EA,et al.Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast. J Am Coll Surg,2005,201(3):327-334.
|
| 3 |
Zhou Z, Zwelling LA, Kawakami Y, et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.Cancer Res,1999, 59(18):4618-4624.
|
| 4 |
Early Breast Cancer Trialists'Collaborative Group(EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials.Lancet,2005,365(9472):1687-1717.
|
| 5 |
Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.JAMA,2001,285(7):885-892.
|
| 6 |
Arriola E,Moreno A,Varela M,et al.Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.Eur J Cancer,2006,42(17):2954-2960.
|
| 7 |
Minisini AM, Di Loreto C, Mansutti M, et al. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett,2005,224(1):133-139.
|
| 8 |
Durbecq V,Desmed C,Paesmans M,et al.Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.Int J Oncol,2004,25(5):1473-1479.
|
| 9 |
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemo therapy on the outcome of women with operable breast cancer. J Clin Oncol,1998,16(8):2672-2685.
|
| 10 |
Fritz P, Cabrera CM, Dippon J, et al. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.Breast Cancer Res,2005,7(3):R374-384.
|
| 11 |
O'Connor JK,Hazard LJ,Avent JM,et al.Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer.Int J Radiat Oncol Biol Phys,2006,65(5):1411-1415.
|
| 12 |
Bozzetti C, Musolino A, Camisa R, et al. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am J Clin Oncol,2006,29(2):171-177.
|